Negative value of CD10−/CD34− immunophenotype in pediatric leukemia and development of a related cell line model for investigating drug resistance
- 05.01.2022
- Research Article
Erschienen in:
- Verfasst von
- N. Aberuyi
- S. Rahgozar
- Erschienen in
- Clinical and Translational Oncology | Ausgabe 6/2022
Abstract
Purpose
Appropriate sub-classification of leukemia according to the immunophenotypic characteristics of the malignant cells may improve therapeutic strategies. The aim of this study was to investigate the prognostic value of CD10/CD34 surface markers in pediatric acute lymphoblastic leukemia (pALL).
Patients and methods
A retrospective cohort study was performed in 79 children with ALL. Possible correlation between leukemia prognosis and CD10 CD34 immunophenotype was assessed using Kaplan–Meier and Cox regression analyses. A CD10- CD34- pre-B-ALL cell line was generated from a patient with resistant ALL. RN95 was characterized using light microscopy, immunophenotyping, karyotyping, and Western blotting. Drug sensitivity and resistant genes’ expression profile were assessed using MTT and RT-PCR assays.
Results
Kaplan–Meier analysis showed negative correlation between CD10/CD34 double negativity and patients’ 2- and 5-year disease-free survival (DFS). Multivariate analysis indicated that the absence of CD10 and CD34 expression in the ALL patients was an independent negative prognostic marker for 2- and 5-year DFS. A novel cell line model, RN95, was developed with similar immunophenotype from a primary relapsed sample. Cells showed p53 positive functionality and demonstrated partial sensitivity to Vincristine, but complete resistance to Cytarabine. Overexpression of ABCB1, ABCA2, and ABCA3 was detected.
Conclusion
In the current study, simultaneous absence of CD10 and CD34 cell surface markers was introduced as an unfavorable prognostic factor in pediatric B-ALL. Moreover, a special cell line was established to help delineation of novel therapeutics for B-ALL drug resistance.
Anzeige
- Titel
- Negative value of CD10−/CD34− immunophenotype in pediatric leukemia and development of a related cell line model for investigating drug resistance
- Verfasst von
-
N. Aberuyi
S. Rahgozar
- Publikationsdatum
- 05.01.2022
- Verlag
- Springer International Publishing
- Erschienen in
-
Clinical and Translational Oncology / Ausgabe 6/2022
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055 - DOI
- https://doi.org/10.1007/s12094-021-02755-x
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
